Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Employees

711

Sector

Biotechnology & Medical Research

Calendar

Mar. 19 - Annual General Meeting

More about the company

Quotes

Date	Price	Change	Volume
26-02-06	64.52 $	-0.19%	24,090,552
26-02-05	64.64 $	-5.02%	3,245,803
26-02-04	68.06 $	-5.66%	2,177,758
26-02-03	72.14 $	-1.18%	2,348,366
26-02-02	73.00 $	+5.29%	2,169,302

Delayed Quote Nasdaq, February 06, 2026 at 04:00 pm EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

64.52USD

Average target price

81.67USD

Spread / Average Target

+26.58%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-06 pm EST			5-day change	1st Jan Change
64.52 ^USD	-0.19%		-6.94%	-2.82%

Feb. 05	Arrowhead Pharmaceuticals, Inc., Q1 2026 Earnings Call, Feb 05, 2026
Feb. 05	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M	MT

Capitalization	9.03B 7.65B 7.01B 6.64B 12.33B 819B 12.89B 81.46B 32.25B 394B 33.88B 33.19B 1,418B	P/E ratio 2026 *	-20.1x	P/E ratio 2027 *	-16.7x
Enterprise value	8.14B 6.89B 6.31B 5.98B 11.1B 737B 11.6B 73.35B 29.04B 355B 30.51B 29.88B 1,277B	EV / Sales 2026 *	17.3x	EV / Sales 2027 *	26.3x
Free-Float	94.28%	Yield 2026 *	-	Yield 2027 *	-

Feb. 05	Arrowhead Pharmaceuticals, Inc., Q1 2026 Earnings Call, Feb 05, 2026
Feb. 05	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M	MT
Feb. 05	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q1 Revenue $264.0M, vs. FactSet Est of $213.9M	MT
Feb. 05	Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
Feb. 04	Ciena Set to Join S&P500	MT
Jan. 27	Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday	MT
Jan. 27	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia	CI
Jan. 27	Arrowhead Pharmaceuticals Doses First Subject in Clinical Trial of Treatment for Mixed Hyperlipidemia	MT
Jan. 22	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $101 From $61, Keeps Buy Rating	MT
Jan. 13	Aligos Therapeutics, Inc. Appoints James Hassard as Executive Vice President and Chief Commercial Officer, Effective January 13, 2026	CI
Jan. 12	Arrowhead Pharmaceuticals issues $700 million of 0.00% convertible notes due 2032 - SEC filing	RE
Jan. 12	Arrowhead Pharmaceuticals, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 07:30 AM
Jan. 08	Arrowhead Pharmaceuticals Prices Offerings of Notes, Common Stock, Pre-Funded Warrants	MT

Jan. 22	B. Riley Raises Price Target on Arrowhead Pharmaceuticals to $101 From $61, Keeps Buy Rating	MT
Jan. 07	Chardan Adjusts Price Target on Arrowhead Pharmaceuticals to $80 From $60, Maintains Buy Rating	MT
Dec. 11	RBC Raises Price Target on Arrowhead Pharmaceuticals to $80 From $52, Keeps Outperform, Speculative Risk	MT
Nov. 19	RBC Raises Price Target on Arrowhead Pharmaceuticals to $52 From $45, Keeps Outperform, Speculative Risk	MT
Nov. 12	Arrowhead Has Large Market Opportunity With Severe Hypertriglyceridemia Treatment, Morgan Stanley Says	MT

Arrowhead Pharmaceuticals, Inc. Stock

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Valuation: Arrowhead Pharmaceuticals, Inc.

Chart: Arrowhead Pharmaceuticals, Inc.

Latest news: Arrowhead Pharmaceuticals, Inc.

Last Transcript: Arrowhead Pharmaceuticals, Inc.

Analysts' recommendations: Arrowhead Pharmaceuticals, Inc.

Press Releases: Arrowhead Pharmaceuticals, Inc.

News in other languages: Arrowhead Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Arrowhead Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Feb. 05	Arrowhead Pharmaceuticals : ARWR FQ1 2026 Script Final	PU
Feb. 05	Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results	BU
Jan. 27	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia	BU
Jan. 20	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results	BU
Jan. 07	Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants	BU

Jan. 05	Arrowhead Pharmaceuticals annonce l’approbation de REDEMPLOMC (plozasiran) par Santé Canada pour réduire les triglycérides chez les adultes atteints du syndrome de chylomicronémie familiale (SCF)
25-09-02	Novartis si assicura diritti di una terapia contro Parkinson
25-09-02	Novartis s'assure les droits d'une thérapie contre Parkinson
25-09-02	Novartis sichert sich Exklusivlizenz für Parkinson-Therapie von Arrowhead
25-09-02	Novartis erhält Lizenzrechte für Parkinson-Behandlung von Arrowhead

1 day	-0.19%
1 week	-6.94%
Current month	-6.94%
1 month	-8.88%
3 months	+62.93%
6 months	+295.59%
Current year	-2.82%

1 week	63.46	76.11
1 month	61.65	76.11
Current year	60.62	76.76
1 year	9.57	76.76
3 years	9.57	76.76
5 years	9.57	93.66
10 years	1.2	93.66

Manager	Title	Age	Since
Christopher Anzalone CEO	Chief Executive Officer	56	2007-11-30
Daniel Apel DFI	Director of Finance/CFO	-	2025-05-12
Peter Carignan CTO	Chief Tech/Sci/R&D Officer	-	2022-07-31

Director	Title	Age	Since
Christopher Anzalone CHM	Chairman	56	-
Mauro Ferrari BRD	Director/Board Member	66	2010-08-18
Michael Perry BRD	Director/Board Member	66	2011-12-18

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ARROWHEAD PHARMACEUTICALS, INC.	-0.19%	-6.94%	+215.04%	+92.54%	9.03B
ARGENX SE	-2.85%	-1.17%	+9.03%	+98.35%	50.29B
WUXI APPTEC CO., LTD.	+0.74%	+2.76%	+68.53%	+6.99%	42.11B
INSMED INCORPORATED	-0.77%	-4.47%	+85.52%	+591.24%	31.96B
BIONTECH SE	+1.02%	-6.27%	-11.11%	-24.36%	26.75B
WUXI BIOLOGICS (CAYMAN) INC.	+0.43%	+1.84%	+78.16%	-40.66%	19.93B
GENMAB A/S	-1.48%	-3.17%	+41.42%	-27.56%	19.08B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.71%	+1.88%	+144.48%	-	12.63B
AKESO, INC.	-0.39%	-8.61%	+59.02%	+123.73%	11.89B
Average	-0.31%	-2.44%	+76.68%	+102.53%	24.85B
Weighted average by Cap.	-0.57%	-1.45%	+56.30%	+115.87%

	2026 *	2027 *
Net sales	470M 398M 365M 345M 641M 42.58B 670M 4.24B 1.68B 20.5B 1.76B 1.73B 73.78B	298M 253M 231M 219M 407M 27.03B 426M 2.69B 1.06B 13.01B 1.12B 1.1B 46.83B
Net income	-453M -384M -352M -333M -618M -41.06B -647M -4.09B -1.62B -19.77B -1.7B -1.66B -71.16B	-552M -467M -428M -406M -753M -50.01B -787M -4.98B -1.97B -24.08B -2.07B -2.03B -86.67B
Net Debt	-900M -762M -698M -661M -1.23B -81.51B -1.28B -8.11B -3.21B -39.24B -3.37B -3.3B -141B	-1.18B -1B -917M -868M -1.61B -107B -1.69B -10.65B -4.22B -51.54B -4.43B -4.34B -186B